| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/18/1997 | WO1997033883A1 Novel pyrimidine compounds useful in treating cytokine mediated diseases |
| 09/18/1997 | WO1997033882A1 Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| 09/18/1997 | WO1997033881A1 Bicyclic-aromatic compounds |
| 09/18/1997 | WO1997033880A1 Methods of treating or preventing interstitial cystitis |
| 09/18/1997 | WO1997033879A1 Compounds and methods for selectively inhibiting activation of the human a3 adenosine receptor |
| 09/18/1997 | WO1997033877A1 Bioconjugates of manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
| 09/18/1997 | WO1997033873A1 Methods of treating or preventing interstitial cystitis |
| 09/18/1997 | WO1997033869A1 N-[(r)-1-{3-(4-piperidyl)propionyl-3-piperidylcarbonyl]-2(s)-acetylamino-beta-alanine as fibrinogen receptor antagonist |
| 09/18/1997 | WO1997033861A1 Anticonvulsant enantiomeric amino acid derivatives |
| 09/18/1997 | WO1997033860A1 Method and compositions for producing analgesia |
| 09/18/1997 | WO1997033859A1 Novel bridged cyclic amino acids as pharmaceutical agents |
| 09/18/1997 | WO1997033858A1 Novel substituted cyclic amino acids as pharmaceutical agents |
| 09/18/1997 | WO1997033856A1 Diaromatic propynyl or dienyl compounds |
| 09/18/1997 | WO1997033855A1 Cinnamylidene camphor derivatives and their use as uv-a protecting agents |
| 09/18/1997 | WO1997033628A1 Polymeric delivery of radionuclides and radiopharmaceuticals |
| 09/18/1997 | WO1997033623A1 OLIGONUCLEOTIDES TARGETED TO ANGIOTENSINOGEN mRNA |
| 09/18/1997 | WO1997033622A2 Delivery of nucleic acids by porphyrins |
| 09/18/1997 | WO1997033620A2 Compounds for treating tumours |
| 09/18/1997 | WO1997033619A1 Improved vision through photodynamic therapy of the eye |
| 09/18/1997 | WO1997033618A1 Targeting macromolecular prodrugs to t lymphocytes |
| 09/18/1997 | WO1997033614A1 Use of coxiella bacteria to treat autoimmune disease |
| 09/18/1997 | WO1997033611A1 Method of killing target cells in harvested cell populations with one or more immunotoxins |
| 09/18/1997 | WO1997033609A1 VASOACTIVE EFFECTS AND FREE RADICAL GENERATION BY β-AMYLOID PEPTIDES |
| 09/18/1997 | WO1997033608A2 Antagonism of endothelin actions |
| 09/18/1997 | WO1997033606A1 PROGRAMMED CELL DEATH AND INTERLEUKIN-1$g(b) |
| 09/18/1997 | WO1997033604A1 Treatment of hiv-infection by interfering with host cell cyclophilin receptor activity |
| 09/18/1997 | WO1997033603A1 Novel peptides which inhibit complement activation |
| 09/18/1997 | WO1997033594A1 Methods of using emu oil and active fractions thereof as an insect repellent |
| 09/18/1997 | WO1997033593A1 A product of heat treatment of uronic acid, food, drink or drug including the product |
| 09/18/1997 | WO1997033592A1 Methods for cell mobilization using in vivo treatment with hyaluronan (ha) |
| 09/18/1997 | WO1997033589A1 Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy |
| 09/18/1997 | WO1997033588A1 Iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
| 09/18/1997 | WO1997033587A1 Method for treating insomnia |
| 09/18/1997 | WO1997033586A1 Method for treating substance abuse |
| 09/18/1997 | WO1997033585A1 Method for treating autism |
| 09/18/1997 | WO1997033584A1 Method for treating excessive aggression |
| 09/18/1997 | WO1997033583A1 Methods of treating or preventing interstitial cystitis |
| 09/18/1997 | WO1997033582A1 Polyamine site antagonist compositions |
| 09/18/1997 | WO1997033581A1 Smoking cessation treatments using naltrexone and related compounds |
| 09/18/1997 | WO1997033580A1 Maintaining kidney function during surgery or trauma |
| 09/18/1997 | WO1997033579A1 Medicaments comprising 5ht1-like receptor agonists with an increased absorption |
| 09/18/1997 | WO1997033578A1 Combination of cis-4-hydroxy-l-proline and n-methyl-cis-4-hydroxy-l-proline for use as a therapeutic agent, in particular in cancer treatment |
| 09/18/1997 | WO1997033577A1 Method for treating bipolar disorder |
| 09/18/1997 | WO1997033575A1 Use of tiamulin for preparing a drug for use as a cancer multidrug resistance reversion agent |
| 09/18/1997 | WO1997033574A1 Sustained-release metal valproate tablets |
| 09/18/1997 | WO1997033573A1 Nasal administration of agents for treatment of delayed onset emesis |
| 09/18/1997 | WO1997033572A1 Method for preventing and treating peripheral neurophathy by administering selegiline |
| 09/18/1997 | WO1997033571A1 Rapid-release microdispersible ecadotril preparation |
| 09/18/1997 | WO1997033570A1 Dosage forms and uses |
| 09/18/1997 | WO1997033569A1 Medicament preparation for angiotensin converting enzyme (ace)-inhibitors |
| 09/18/1997 | WO1997033567A1 Disinfectant effervescent tablet formulation |
| 09/18/1997 | WO1997033566A2 Composition and dosage form comprising opioid antagonist |
| 09/18/1997 | WO1997033565A1 Nucleoside compositions containing paracellular absorption enhancers |
| 09/18/1997 | WO1997033564A1 Agglomerates containing beta-lactam compounds |
| 09/18/1997 | WO1997033562A1 Ophthalmological composition of the type which undergoes liquid-gel phase transition |
| 09/18/1997 | WO1997033552A1 Water soluble paclitaxel prodrugs |
| 09/18/1997 | WO1997033474A1 Targeted site specific drug delivery compositions and method of use |
| 09/18/1997 | WO1997033473A1 Method for reducing bcl-2 expressing cells resistance to death |
| 09/18/1997 | WO1997026866A3 Preparations of non-steroidal analgesics |
| 09/18/1997 | WO1997025440A3 Methods and compositions for diagnosis of hyperhomocysteinemia |
| 09/18/1997 | WO1997025351A3 INHIBITORS OF MAdCAM-1-MEDIATED INTERACTIONS AND METHODS OF USE THEREFOR |
| 09/18/1997 | WO1997025343A3 Antithrombotic agents and methods of use |
| 09/18/1997 | WO1997025067A3 Polymers |
| 09/18/1997 | WO1997022695A3 Nucleotide sequences, proteins, drugs and diagnostic agents for treating cancer |
| 09/18/1997 | WO1997022354A3 Use of a medicament and use of mixture of substances to produce a medicament |
| 09/18/1997 | WO1997020569A3 Bioartificial devices and cellular matrices therefor |
| 09/18/1997 | WO1997007815A3 Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis |
| 09/18/1997 | DE19611789A1 Increasing effectiveness of cytostatics under influence of efflux pump inhibitors |
| 09/18/1997 | DE19610635A1 Sequentielle Estrogen/Progesteronantagonist-Kombination für die Hormonersatz-Therapie Sequential estrogen / progesterone antagonist combination for hormone replacement therapy |
| 09/18/1997 | DE19610396A1 Topical analgesic preparations with high di:methyl sulphate content |
| 09/18/1997 | DE19610357A1 Geminale Difluorderivate von Phenylacetamid und Phenylessigsäure, Verfahren zu deren Herstellung sowie deren pharmazeutische Zusammensetzungen Geminal difluoro of phenylacetamide and phenylacetic acid, a process for their preparation and their pharmaceutical compositions |
| 09/18/1997 | DE19610348A1 Treatment of tumours |
| 09/18/1997 | CA2250319A1 Polyvalent polymers for the treatment of rotavirus infection |
| 09/18/1997 | CA2250288A1 Methods of treating or preventing interstitial cystitis |
| 09/18/1997 | CA2249733A1 Spirocycle integrin inhibitors |
| 09/18/1997 | CA2249011A1 Bioconjugates of manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
| 09/18/1997 | CA2248964A1 Iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
| 09/18/1997 | CA2248932A1 Oligonucleotides targeted to angiotensinogen mrna |
| 09/18/1997 | CA2248927A1 Smooth muscle cell lim protein |
| 09/18/1997 | CA2248905A1 Method for treating bipolar disorder |
| 09/18/1997 | CA2248881A1 Ophthalmological composition of the type which undergoes liquid-gel phase transition |
| 09/18/1997 | CA2248809A1 N-¬(r)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl|-2(s)-acetylamino-beta-alanine as fibrinogen receptor antagonist |
| 09/18/1997 | CA2248765A1 Combination of cis-4-hydroxy-l-proline and n-methyl-cis-4-hydroxy-l-proline for use as a therapeutic agent, in particular in cancer treatment |
| 09/18/1997 | CA2248758A1 Method for treating insomnia |
| 09/18/1997 | CA2248741A1 Use of olanzapine for treating autism |
| 09/18/1997 | CA2248738A1 Use of olanzapine for treating substance abuse |
| 09/18/1997 | CA2248707A1 Clostridium perfringens vaccines |
| 09/18/1997 | CA2248684A1 Immunity to trypanosomatids species |
| 09/18/1997 | CA2248673A1 Method and compositions for producing analgesia |
| 09/18/1997 | CA2248648A1 A product of heat treatment of uronic acid, food, drink or drug including the product |
| 09/18/1997 | CA2248620A1 Method of killing target cells in harvested cell populations with one or more immunotoxins |
| 09/18/1997 | CA2248613A1 Vasoactive effects and free radical generation by .beta.-amyloid peptides |
| 09/18/1997 | CA2248612A1 Recombinant adenoviral vectors for human tumour gene therapy |
| 09/18/1997 | CA2248586A1 Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| 09/18/1997 | CA2248551A1 Programmed cell death and interleukin-1.beta. |
| 09/18/1997 | CA2248549A1 Extracellular matrix signalling molecules |
| 09/18/1997 | CA2248538A1 Targeted delivery of genes encoding interferon |
| 09/18/1997 | CA2248537A1 Immunomodulatory peptides of vespid antigen 5 |
| 09/18/1997 | CA2248192A1 Treatment of hiv-infection by interfering with host cell cyclophilin receptor activity |
| 09/18/1997 | CA2248165A1 Cinnamylidene camphor derivatives and their use as uv-a protecting agents |